personal genome service
Almost two years after the FDA first told 23andMe to halt sales on its mail-order direct-to-consumer genetic testing service for disease risks, the company has relaunched a version of its new Personal Genome Service (PGS), which now meets FDA standards.
Google-backed 23andMe is finally relaunching its mail-order personal genome service -- just not in the United States.